[go: up one dir, main page]

MX2020002123A - Sales de ribociclib y formas en estado sólido de las mismas. - Google Patents

Sales de ribociclib y formas en estado sólido de las mismas.

Info

Publication number
MX2020002123A
MX2020002123A MX2020002123A MX2020002123A MX2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A MX 2020002123 A MX2020002123 A MX 2020002123A
Authority
MX
Mexico
Prior art keywords
ribociclib
solid state
state forms
salts
forms
Prior art date
Application number
MX2020002123A
Other languages
English (en)
Inventor
Alexandr Jegorov
Paolo Simone Tiseni
Helena Ceric
Elisa Vergani
Hana Kantor
Piero Paravidino
Nikolina Janton
Christian Galluzzo
Original Assignee
Sicor Soc It Corticosteroidi S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Soc It Corticosteroidi S R L filed Critical Sicor Soc It Corticosteroidi S R L
Publication of MX2020002123A publication Critical patent/MX2020002123A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a formas en estado sólido de Ribociclib, sales de Ribociclib que incluyen succinato de Ribociclib y formas en estado sólido de las mismas, así como a procesos para la preparación de las mismas y composiciones farmacéuticas de las mismas.
MX2020002123A 2017-08-25 2018-08-22 Sales de ribociclib y formas en estado sólido de las mismas. MX2020002123A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762550208P 2017-08-25 2017-08-25
US201762555170P 2017-09-07 2017-09-07
US201762577446P 2017-10-26 2017-10-26
US201762593319P 2017-12-01 2017-12-01
PCT/US2018/047434 WO2019040567A1 (en) 2017-08-25 2018-08-22 RIBOCICLIB SALTS AND SOLID STATE FORMS THEREOF

Publications (1)

Publication Number Publication Date
MX2020002123A true MX2020002123A (es) 2020-09-18

Family

ID=63449728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002123A MX2020002123A (es) 2017-08-25 2018-08-22 Sales de ribociclib y formas en estado sólido de las mismas.

Country Status (10)

Country Link
US (2) US11155545B2 (es)
EP (2) EP4327880A3 (es)
KR (1) KR102715956B1 (es)
CA (1) CA3073936A1 (es)
ES (1) ES2968174T3 (es)
HR (1) HRP20240026T1 (es)
IL (1) IL272859A (es)
MX (1) MX2020002123A (es)
SI (1) SI3672968T1 (es)
WO (1) WO2019040567A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3231805B1 (en) 2014-12-12 2020-03-04 Crystal Pharmatech Co. Ltd. Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Novel crystalline form of ribociclib succinate
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
WO2020225827A1 (en) * 2019-05-08 2020-11-12 Mylan Laboratories Limited Novel polymorphs of ribociclib succinate
CN112010857B (zh) * 2019-05-30 2021-11-05 常州制药厂有限公司 一种瑞博西尼单丁二酸盐的晶型
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
EP4313987B1 (en) 2021-04-01 2026-01-14 KRKA, d.d., Novo mesto Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
AU2024244511A1 (en) 2023-03-27 2025-09-25 Novartis Ag Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
WO2025144118A1 (en) * 2023-12-27 2025-07-03 Deva Holding Novel polymorph of ribociclib dihydrochloride dihydrate and method of preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
US20120115878A1 (en) * 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CN105111215B (zh) * 2014-12-12 2019-06-18 苏州晶云药物科技股份有限公司 一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
EP3231805B1 (en) * 2014-12-12 2020-03-04 Crystal Pharmatech Co. Ltd. Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
EP3156406A1 (en) 2015-10-14 2017-04-19 ratiopharm GmbH Crystalline forms of ribociclib free base
WO2019150181A1 (en) * 2018-02-05 2019-08-08 Biophore India Pharmaceuticals Pvt Ltd Improved process for the preparation of 7-cyclopentyl-n, n-dimethyl-2-(5-(piperazin-1-yl) pyridin-2-ylaminuteso)-7h-pyrrolo[2,3-d] pyrimidine-6-carboxamide succinate (ribociclib succinate) and its crystalline forms thereof
TWI675662B (zh) * 2018-05-17 2019-11-01 中化合成生技股份有限公司 瑞博西尼琥珀酸鹽（Ｒｉｂｏｃｉｃｌｉｂ ｓｕｃｃｉｎａｔｅ ｓａｌｔ）晶型Ｂ、Ｃ及Ｄ與其衍生物，以及其等之製造方法與藥物組合物
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Also Published As

Publication number Publication date
US20220041598A1 (en) 2022-02-10
KR102715956B1 (ko) 2024-10-10
EP3672968B1 (en) 2023-11-01
EP4327880A2 (en) 2024-02-28
US20200190084A1 (en) 2020-06-18
ES2968174T3 (es) 2024-05-08
KR20200074942A (ko) 2020-06-25
US12421227B2 (en) 2025-09-23
IL272859A (en) 2020-04-30
EP3672968A1 (en) 2020-07-01
WO2019040567A1 (en) 2019-02-28
US11155545B2 (en) 2021-10-26
SI3672968T1 (sl) 2024-03-29
HRP20240026T1 (hr) 2024-03-29
EP4327880A3 (en) 2024-05-22
CA3073936A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
DK3577110T3 (da) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl-substituerede forbindelser som hiv-inhibitorer
SV2018005610A (es) Derivados de oxopiridina sustituidos
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
MX373320B (es) Compuestos inhibidores de pde2.
EA201591397A1 (ru) Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса
DOP2017000073A (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
MX393092B (es) Bis-compuestos para dispositivos opticamente activos.
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
EA201791716A1 (ru) Фармацевтический состав
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2